THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。手术期间和手术后，给予静脉输液以补充血液和液体流失是一种标准程序。通常给予的液体是盐基溶液。这些溶液分布到身体的血液和组织中。我们认为某些药物（β -肾上腺素能药物）影响静脉输液的分布。该项目的具体目标是找出液体从血液中进入组织的原因，以及药物（β -肾上腺素能药物）如何影响这一过程。我们建议测试短时间内静脉输液的效果。我们想知道有多少液体留在血液中有多少液体进入组织。为了进行这项研究，需要从腿部采集一系列血液样本和测量数据。这项研究的一部分是研究流体在正常状态下的分布。这项研究的另一部分是观察当患者服用了-肾上腺素能拮抗剂（-阻滞剂）或-肾上腺素能激动剂后，体液的分布是否发生了变化。出于安全和科学考虑，我们将在整个研究期间测量生命体征。我们将只招收年龄在18岁到50岁之间的健康人群。根据统计学家的判断，总共需要进行48项研究。这些研究的重要性将使医生1)更好地了解液体疗法2)关于某些药物如何影响液体疗法的信息3)更好的液体疗法计划可能会减少疾病和死亡。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. During and after surgery it is a standard procedure to administer intravenous fluid therapy to replace blood and fluid losses. Fluids normally given are saline-based solutions. These solutions distribute into the blood and tissues of the body. We suggest that certain medicines (beta-adrenergic agents) affect the distribution of intravenous fluid therapy. The specific aims of this project are to find out what makes fluid to move out from the blood into the tissues and how medicines (beta-adrenergic agents) may affect this. We propose to test the affect of giving intravenous fluid over a short period of time. We want to know how much of the fluid stays in the blood and how much fluid goes into the tissues. In order to do this study, a series of blood samples and measurements are needed from the leg. One part of this study is to study how fluids distribute in a normal state. Another part of this study is to see if distribution of fluid changes when patients are given medications called beta-adrenergic antagonist (beta-blocker) or a beta-adrenergic agonist. We will measure vital signs throughout the study period for safety and for scientific reasons. We will enroll only healthy people between the ages of 18 and 50 years. As determined by a statistician, a total of 48 studies will be needed. The importance of these studies will give doctors 1) a better understanding of fluid therapy 2) information about how certain medicines impact fluid therapy 3) a better fluid therapy plan that may decrease illness and death.